top of page
REVERT
OFFICIAL TITLE: A MULTICENTER, RANDOMIZED, PHASE II TRIAL EVALUATING THE EFFICACY OF ERIBULIN MONOTHERAPY AND ERIBULIN PLUS ENDOCRINE THERAPY IN LOCALLY-RECURRENT OR METASTATIC BREAST CANCER PATIENTS AFTER PROGRESSION ON ENDOCRINE THERAPY (REVERT).
CLINICAL TRIAL DETAILS
THE PRIMARY ENDPOINT IS THE OVERALL RESPONSE RATE IN THE ARM CORRESPONDING TO THE PATIENTS TREATED WITH ERIBULIN IN COMBINATION WITH AROMATASE INHIBITOR THERAPY BASED ON LOCAL INVESTIGATOR’S ASSESSMENT ACCORDING TO RECIST V.1.1
​
REVERT IS A SIMON’S TWO-STAGE ADMISSIBLE DESIGN CLINICAL TRIAL, 60 PATIENTS WILL BE INCLUDED, 22 IN STAGE I AND 38 IN STAGE II.
​
PATIENTS WILL RECEIVE ERIBULIN INJECTIONS INTRAVENOUSLY ON DAYS 1 AND 8 OF EVERY 21- DAY CYCLE, ALONE OR IN COMBINATION WITH ENDOCRINE THERAPY (AROMATASE INHIBITOR).
​
REVERT AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
BREAST
II
60
9
Spain
N
SITES
COUNTRY
STATUS
Closing
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
ESMO 2022 – DOWNLOAD THE POSTER
AACR 2019 – DOWNLOAD THE POSTER
REVERT SITES
SPAIN
Hospital Universitario Miguel Servet
SPAIN
Complejo Hospitalario de Jaén
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Hospital Universitario La Paz
SPAIN
Hospital Universitario de León
SPAIN
Hospital Son Llatzer
SPAIN
Hospital Universitari Dexeus
SPAIN
Hospital Universitario Dr. Peset
SPAIN
Institut Català d' Oncologia Girona (ICO)
bottom of page